A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of ABBV-722 in Healthy Adult Subjects
The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Illinois
-
Grayslake、Illinois、アメリカ、60030
- Acpru /Id# 282143
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Laboratory values meet the criteria specified in the protocol.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
Exclusion Criteria:
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
- Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration.
- Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment.
- Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Period 1 & 2
In Period 1, participants will receive a single dose of ABBV-722. In Period 2, participants will receive multiple daily doses of Itraconazole and a single dose of ABBV-722. |
Oral Tablet Oral Capsule |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of ABBV-722
時間枠:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
Cmax of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Time to Cmax (Tmax) of ABBV-722
時間枠:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
Tmax of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722
時間枠:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
AUCt of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722
時間枠:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
AUCinf of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Terminal Phase Elimination Rate Constant (β) of ABBV-722
時間枠:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
β of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-722
時間枠:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
t1/2 of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Number of Participants with Adverse Events (AEs)
時間枠:Up to Approximately 45 Days
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 45 Days
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。